Skip to content

US · GPCR · BIOTECHNOLOGY

Structure Therapeutics Inc. (GPCR) intrinsic value and stock valuation

$16.13as of 2026-11-21 · Mkt cap 2.91B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Structure Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values GPCR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GPCR’s statements →

Structure Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 structuretx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-141.2M
20202025
Free cash flow
-$-225.81M
20202025
Total equity
$1.52B
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-287.57M-$-158.23M-$-102.78M-$-52.56M-$-37.7M
Net income-$-141.2M-$-122.53M-$-89.62M-$-51.32M-$-40.01M
EPSd-$-2.39M-$-2.33M-$-2.44M-$-1.4M-$-1.09M
Operating cash flow-$-222.2M-$-116.64M-$-79.49M-$-46.12M-$-32.16M
Capital expenditure-$-3.61M-$-1.29M-$-2.17M-$-150K-$-1.21M
Free cash flow-$-225.81M-$-117.93M-$-81.66M-$-46.27M-$-33.37M
Total assets$1.58B$903.3M$482M$97.8M$111.2M
Total debt$6.49M$3.86M$5.45M$260K$620K
Net debt-$-793.14M-$-165.65M-$-124.34M-$-25.83M-$-104.68M
Total equity$1.52B$864.8M$453M-$-115.14M-$-64.73M
Cash and short-term investments$1.45B$883.5M$467.3M$90.8M$107.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$3.9M$0.00$0.00$0.00$0.00
Gross profit-$-3.9M$0.00$0.00$0.00$0.00
Research and development expenses$225.3M$108.8M$70.1M$36.2M$29.1M
Selling, general and administrative expenses$61.6M$49.4M$32.7M$16.4M$8.59M
Other expenses-$-3.14M$0.00$0.00$0.00$0.00
Operating expenses$283.7M$158.2M$102.8M$52.6M$37.7M
Cost and expenses$287.6M$158.2M$102.8M$52.6M$37.7M
Interest income$36M$36M$13.4M$1.26M$0.00
Interest expense$0.00$0.00$13.4M$0.00$120K
Depreciation and amortization$3.9M$990K$290K$280K$70K
Ebitda-$-136.79M-$-121.22M-$-75.7M-$-51.03M-$-37.62M
Operating income-$-287.57M-$-158.23M-$-102.78M-$-52.56M-$-37.7M
Total other income/expenses, net$146.5M$36M$13.4M$1.26M-$-120K
Income before tax-$-140.69M-$-122.22M-$-89.38M-$-51.3M-$-37.82M
Income tax expense$520K$310K$240K$20K$230K
Net income-$-141.2M-$-122.53M-$-89.62M-$-51.32M-$-40.01M
Weighted average shares outstanding$59.2M$52.6M$36.7M$36.6M$36.6M
Weighted average diluted shares outstanding$59.2M$52.6M$36.7M$36.6M$36.6M
Balance sheet
20252024202320222021
Cash and short-term investments$1.45B$883.5M$467.3M$90.8M$107.3M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.57B$891.2M$473.6M$93.1M$109.3M
Property, plant and equipment, net$12.9M$7.01M$8.36M$1.29M$1.79M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$13.6M$12.1M$8.41M$4.76M$1.91M
Total assets$1.58B$903.3M$482M$97.8M$111.2M
Accounts payable$13.9M$8.02M$4.74M$6.01M$3.48M
Short-term debt$2.88M$1.7M$1.44M$260K$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$63.3M$36M$24.7M$13M$8.66M
Long-term debt$3.61M$2.16M$4.01M$0.00$270K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.26M$2.47M$4.31M$200M$167.2M
Capital lease obligations$2.88M$3.86M$5.45M$260K$620K
Total liabilities$67.5M$38.5M$29.1M$213M$175.9M
Common stock$20K$20K$10K$0.00$0.00
Retained earnings-$-470.3M-$-329.1M-$-206.57M-$-116.95M-$-64.74M
Accumulated other comprehensive income (loss)$1.05M$910K$520K-$-110K$0.00
Total equity$1.52B$864.8M$453M-$-115.14M-$-64.73M
Total investments$646.6M$714M$337.5M$64.8M$2M
Total debt$6.49M$3.86M$5.45M$260K$620K
Net debt-$-793.14M-$-165.65M-$-124.34M-$-25.83M-$-104.68M
Cash flow statement
20252024202320222021
Net income-$-141.2M-$-122.53M-$-89.62M-$-51.32M-$-38.05M
Depreciation and amortization$1.33M$990K$290K$280K$70K
Stock-based compensation$29M$18.8M$8.19M$2.51M$1.49M
Change in working capital-$-88.27M$2.96M$6.97M$2.97M$4.06M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.76M$3.31M-$-860K$2.15M$1.9M
Net cash provided by operating activities-$-222.2M-$-116.64M-$-79.49M-$-46.12M-$-32.16M
Investments in property, plant and equipment-$-3.61M-$-1.29M-$-2.17M-$-150K-$-1.21M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$89.8M-$-358.91M-$-268.34M-$-62.11M$17.9M
Common stock issued$767.2M$514.6M$472.3M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$762.5M$515.3M$451.5M$29M$103.3M
Net change in cash$630.1M$39.7M$103.7M-$-79.21M$89M
Cash at end of period$799.6M$169.5M$129.8M$26.1M$105.3M
Operating cash flow-$-222.2M-$-116.64M-$-79.49M-$-46.12M-$-32.16M
Capital expenditure-$-3.61M-$-1.29M-$-2.17M-$-150K-$-1.21M
Free cash flow-$-225.81M-$-117.93M-$-81.66M-$-46.27M-$-33.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Structure Therapeutics Inc.

        Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

        CEO
        Raymond C. Stevens
        Employees
        220
        Beta
        -1.57

        Explore

        Frequently asked questions

        What is the intrinsic value of Structure Therapeutics Inc. (GPCR)?

        InvestorsCraft does not currently publish an intrinsic value for GPCR. How the IC value is calculated.

        Is GPCR undervalued?

        InvestorsCraft does not publish an undervaluation signal for GPCR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.